{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:29:04Z","timestamp":1795026544482,"version":"4.10.2"},"reference-count":93,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0353","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T01:28:02Z","timestamp":1645493282000},"source":"Crossref","is-referenced-by-count":38,"title":["Pregnancy and autoimmune disease: diseases of the nervous system, connective tissue, and the bowel"],"prefix":"10.3238","author":[{"given":"Waltraut Maria","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fischer-Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gembruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"10.3238\/arztebl.m2021.0353_ref1","doi-asserted-by":"crossref","unstructured":"J\u00f8lving LR, Nielsen J, Kesmodel US, Nielsen RG, Beck-Nielsen SS, N\u00f8rg\u00e5rd BM: Prevalence of maternal chronic diseases during pregnancy &#8211; a nationwide population based study from 1989 to 2013. Acta Obstet Gynecol Scand 2016; 95: 1295&#8211;304.","DOI":"10.1111\/aogs.13007"},{"key":"10.3238\/arztebl.m2021.0353_ref2","doi-asserted-by":"crossref","unstructured":"Kersten I, Lange AE, Haas JP, et al.: Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth 2014; 14: 75.","DOI":"10.1186\/1471-2393-14-75"},{"key":"10.3238\/arztebl.m2021.0353_ref3","doi-asserted-by":"crossref","unstructured":"Brown CC, Adams CE, George KE, Moore JE: Associations between comorbidities and severe maternal morbidity. Obstet Gynecol 2020; 136: 892&#8211;901.","DOI":"10.1097\/AOG.0000000000004057"},{"key":"10.3238\/arztebl.m2021.0353_ref4","unstructured":"Knight M, Bunch K, Tuffnell D, et al. (eds): Saving lives, improving mothers&#8217; care: lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity. Oxford 2019; 2015&#8211;7."},{"key":"10.3238\/arztebl.m2021.0353_ref5","unstructured":"Richtlinien des Gemeinsamen Bundesausschusses \u00fcber die \u00e4rztliche Betreuung w\u00e4hrend der Schwangerschaft und nach der Entbindung (&#8222;Mutterschafts-Richtlinien&#8220;): In der Fassung vom 10. Dezember 1985 (ver\u00f6ffentlicht im Bundesanzeiger Nr. 60 a vom 27. M\u00e4rz 1986) zuletzt ge\u00e4ndert am 20. August 2020 ver\u00f6ffentlicht im Bundesanzeiger AT 23.11.2020 B3 in Kraft getreten am 24. November 2020."},{"key":"10.3238\/arztebl.m2021.0353_ref6","unstructured":"European Medicines Agency\/Committee for Medicinal Products for Human Use (EMEA\/CHMP): Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. London 2008."},{"key":"10.3238\/arztebl.m2021.0353_ref7","unstructured":"Department of Health and Human Services Food and Drug: Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling 2014. www.federalregister.gov\/documents\/2014\/12\/04\/2014&#8211;28241\/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for (last accessed on 8 February 2022)."},{"key":"10.3238\/arztebl.m2021.0353_ref8","doi-asserted-by":"crossref","unstructured":"Krysko KM, Graves JS, Dobson R, et al.: Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord 2020; 13: 1756286420936166.","DOI":"10.1177\/1756286420936166"},{"key":"10.3238\/arztebl.m2021.0353_ref9","doi-asserted-by":"crossref","unstructured":"Mao-Draayer Y, Thiel S, Mills EA, et al.: Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol 2020; 16: 154&#8211;70.","DOI":"10.1038\/s41582-020-0313-y"},{"key":"10.3238\/arztebl.m2021.0353_ref10","doi-asserted-by":"crossref","unstructured":"Hellwig K, Haghikia A, Gold R: Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010; 257: 580&#8211;3.","DOI":"10.1007\/s00415-009-5376-z"},{"key":"10.3238\/arztebl.m2021.0353_ref11","doi-asserted-by":"crossref","unstructured":"K\u00fcmpfel T, Thiel S, Meinl I, et al.: Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany. Neurol Neuroimmunol Neuroinflamm 2020; 8: e913.","DOI":"10.1212\/NXI.0000000000000913"},{"key":"10.3238\/arztebl.m2021.0353_ref12","doi-asserted-by":"crossref","unstructured":"Ciplea AI, Langer-Gould A, Vries Ad, et al.: Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2020; 7: e723.","DOI":"10.1212\/NXI.0000000000000723"},{"key":"10.3238\/arztebl.m2021.0353_ref13","doi-asserted-by":"crossref","unstructured":"Altintas A, Dargvainiene J, Schneider-Gold C, et al.: Gender issues of antibody-mediated diseases in neurology: (NMOSD\/autoimmune encephalitis\/MG). Ther Adv Neurol Disord 2020; 13: 1756286420949808.","DOI":"10.1177\/1756286420949808"},{"key":"10.3238\/arztebl.m2021.0353_ref14","doi-asserted-by":"crossref","unstructured":"Grover KM, Sripathi N: Myasthenia gravis and pregnancy. Muscle Nerve 2020; 62: 664&#8211;72.","DOI":"10.1002\/mus.27064"},{"key":"10.3238\/arztebl.m2021.0353_ref15","doi-asserted-by":"crossref","unstructured":"Nicholls-Dempsey L, Czuzoj-Shulman N, Abenhaim HA: Maternal and neonatal outcomes among pregnant women with myasthenia gravis. J Perinat Med 2020; 48: 793&#8211;8.","DOI":"10.1515\/jpm-2020-0163"},{"key":"10.3238\/arztebl.m2021.0353_ref16","doi-asserted-by":"crossref","unstructured":"Kishore S, Mittal V, Majithia V: Obstetric outcomes in women with rheumatoid arthritis: results from nationwide inpatient sample database 2003&#8211;2011. Semin Arthritis Rheum 2019; 49: 236&#8211;40.","DOI":"10.1016\/j.semarthrit.2019.03.011"},{"key":"10.3238\/arztebl.m2021.0353_ref17","doi-asserted-by":"crossref","unstructured":"Wallenius M, Salvesen K\u00c5, Daltveit AK, Skomsvoll JF: Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand 2014; 93: 302&#8211;7.","DOI":"10.1111\/aogs.12324"},{"key":"10.3238\/arztebl.m2021.0353_ref18","doi-asserted-by":"crossref","unstructured":"Jethwa H, Lam S, Smith C, Giles I: Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis. J Rheumatol 2019; 46: 245&#8211;50.","DOI":"10.3899\/jrheum.180226"},{"key":"10.3238\/arztebl.m2021.0353_ref19","doi-asserted-by":"crossref","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, et al.: 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020; 72: 529&#8211;56.","DOI":"10.1002\/art.41191"},{"key":"10.3238\/arztebl.m2021.0353_ref20","doi-asserted-by":"crossref","unstructured":"Bundhun PK, Soogund MZS, Huang F: Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001&#8211;2016. J Autoimmun 2017; 79: 17&#8211;27.","DOI":"10.1016\/j.jaut.2017.02.009"},{"key":"10.3238\/arztebl.m2021.0353_ref21","doi-asserted-by":"crossref","unstructured":"Skorpen CG, Lydersen S, Gilboe I-M, et al.: Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis 2018; 77: 264&#8211;9.","DOI":"10.1136\/annrheumdis-2017-211641"},{"key":"10.3238\/arztebl.m2021.0353_ref22","doi-asserted-by":"crossref","unstructured":"Buyon JP, Kim MY, Guerra MM, et al.: Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015; 163: 153&#8211;63.","DOI":"10.7326\/M14-2235"},{"key":"10.3238\/arztebl.m2021.0353_ref23","doi-asserted-by":"crossref","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.: EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296&#8211;304.","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"10.3238\/arztebl.m2021.0353_ref24","doi-asserted-by":"crossref","unstructured":"van der Woude CJ, Ardizzone S, Bengtson MB, et al.: The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107&#8211;24.","DOI":"10.1093\/ecco-jcc\/jju006"},{"key":"10.3238\/arztebl.m2021.0353_ref25","doi-asserted-by":"crossref","unstructured":"Mahadevan U, Robinson C, Bernasko N, et al.: Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Inflamm Bowel Dis 2019; 25: 627&#8211;41.","DOI":"10.1093\/ibd\/izz037"},{"key":"10.3238\/arztebl.m2021.0353_ref26","doi-asserted-by":"crossref","unstructured":"Rottenstreich A, Shifman Z, Grisaru-Granovksy S, Mishael T, Koslowsky B, Bar-Gil Shitrit A: Factors associated with inflammatory bowel disease flare during pregnancy among women with preconception remission. Dig Dis Sci 2021; 66: 1189&#8211;94.","DOI":"10.1007\/s10620-020-06282-7"},{"key":"10.3238\/arztebl.m2021.0353_ref27","doi-asserted-by":"crossref","unstructured":"Forbes A, Escher J, H\u00e9buterne X, et al.: ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr 2017; 36: 321&#8211;47.","DOI":"10.1016\/j.clnu.2016.12.027"},{"key":"10.3238\/arztebl.m2021.0353_ref28","doi-asserted-by":"crossref","unstructured":"Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J: UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2020; 188: 819&#8211;30.","DOI":"10.1111\/bjh.16221"},{"key":"10.3238\/arztebl.m2021.0353_ref29","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Lebwohl B, Ekbom A, et al.: Outcomes of pregnancies for women undergoing endoscopy while they were pregnant: a nationwide cohort study. Gastroenterology 2017; 152: 554&#8211;63.e9.","DOI":"10.1053\/j.gastro.2016.10.016"},{"key":"10.3238\/arztebl.m2021.0353_ref30","doi-asserted-by":"crossref","unstructured":"Foulon A, Dupas J-L, Sabbagh C, et al.: Defining the most appropriate delivery mode in women with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2017; 23: 712&#8211;20.","DOI":"10.1097\/MIB.0000000000001112"},{"key":"10.3238\/arztebl.m2021.0353_ref31","doi-asserted-by":"crossref","unstructured":"Mahadevan U, Long MD, Kane SV, et al.: Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021; 160: 1131&#8211;9.","DOI":"10.1053\/j.gastro.2020.11.038"},{"key":"10.3238\/arztebl.m2021.0353_ref32","doi-asserted-by":"crossref","unstructured":"ACOG Committee: Opinion No. 743: Low-dose aspirin use during pregnancy. Obstet Gynecol 2018; 132: e44&#8211;e52.","DOI":"10.1097\/AOG.0000000000002708"},{"key":"10.3238\/arztebl.m2021.0353_ref33","unstructured":"National Institute for Health and Care Excellence: Hypertension in pregnancy: diagnosis and management (NG133). www.nice.org.uk\/guidance\/ng133 (last accessed on 8 February 2022)."},{"key":"10.3238\/arztebl.m2021.0353_ref34","doi-asserted-by":"crossref","unstructured":"Pruetz JD, Miller JC, Loeb GE, Silka MJ, Bar-Cohen Y, Chmait RH: Prenatal diagnosis and management of congenital complete heart block. Birth Defects Res 2019; 111: 380&#8211;8.","DOI":"10.1002\/bdr2.1459"},{"key":"10.3238\/arztebl.m2021.0353_ref35","doi-asserted-by":"crossref","unstructured":"Fredi M, Andreoli L, Bacco B, et al.: First report of the Italian registry on immune-mediated congenital heart block (Lu.Ne Registry). Front Cardiovasc Med 2019; 6: 11.","DOI":"10.3389\/fcvm.2019.00011"},{"key":"10.3238\/arztebl.m2021.0353_ref36","doi-asserted-by":"crossref","unstructured":"Gilhus NE: Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 2020; 11: 554.","DOI":"10.3389\/fneur.2020.00554"},{"key":"10.3238\/arztebl.m2021.0353_ref37","doi-asserted-by":"crossref","unstructured":"Mor G, Aldo P, Alvero AB: The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 2017; 17: 469&#8211;82.","DOI":"10.1038\/nri.2017.64"},{"key":"10.3238\/arztebl.m2021.0353_ref38","doi-asserted-by":"crossref","unstructured":"Han VX, Patel S, Jones HF, et al.: Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Transl Psychiatry 2021; 11: 71.","DOI":"10.1038\/s41398-021-01198-w"},{"key":"10.3238\/arztebl.m2021.0353_ref39","doi-asserted-by":"crossref","unstructured":"Luyckx VA, Brenner BM: Birth weight, malnutrition and kidney-associated outcomes&#8212;a global concern. Nat Rev Nephrol 2015; 11: 135&#8211;49.","DOI":"10.1038\/nrneph.2014.251"},{"key":"10.3238\/arztebl.m2021.0353_ref40","unstructured":"Warrington NM, Beaumont RN, Horikoshi M, et al.: Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nat Genet 2019; 51: 804&#8211;14."},{"key":"10.3238\/arztebl.m2021.0353_ref41","unstructured":"Huang T, Wang T, Zheng Y, et al.: Association of birth weight with type 2 diabetes and glycemic traits: a Mendelian randomization study. JAMA Netw Open 2019; 2: e1910915."},{"key":"10.3238\/arztebl.m2021.0353_ref42","doi-asserted-by":"crossref","unstructured":"Mylotte D, Pilote L, Ionescu-Ittu R, et al.: Specialized adult congenital heart disease care: the impact of policy on mortality. Circulation 2014; 129: 1804&#8211;12.","DOI":"10.1161\/CIRCULATIONAHA.113.005817"},{"key":"10.3238\/arztebl.m2021.0353_ref43","doi-asserted-by":"crossref","unstructured":"Li DK, Yang C, Andrade S, Tavares V, Ferber JR: Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343: d5931.","DOI":"10.1136\/bmj.d5931"},{"key":"10.3238\/arztebl.m2021.0353_ref44","doi-asserted-by":"crossref","unstructured":"Patel SS, Burns TL: Nongenetic risk factors and congenital heart defects. Pediatr Cardiol 2013; 34: 1535&#8211;55.","DOI":"10.1007\/s00246-013-0775-4"},{"key":"10.3238\/arztebl.m2021.0353_ref45","unstructured":"Embryotox &#8211; Arzneimittelsicherheit in Schwangerschaft und Stillzeit. www.embryotox.de (last accessed on 8 February 2022)."},{"key":"10.3238\/arztebl.m2021.0353_ref46","doi-asserted-by":"crossref","unstructured":"Orton SM, Herrera BM, Yee IM, et al.: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932&#8211;6.","DOI":"10.1016\/S1474-4422(06)70581-6"},{"key":"10.3238\/arztebl.m2021.0353_ref47","doi-asserted-by":"crossref","unstructured":"Ng SC, Shi HY, Hamidi N, et al.: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769&#8211;78.","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"10.3238\/arztebl.m2021.0353_ref48","doi-asserted-by":"crossref","unstructured":"Selinger CP, Eaden J, Selby W, et al.: Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013; 7: e206&#8211;13.","DOI":"10.1016\/j.crohns.2012.09.010"},{"key":"10.3238\/arztebl.m2021.0353_ref49","doi-asserted-by":"crossref","unstructured":"O&#8217;Toole A, Nwanne O, Tomlinson T: Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 2015; 60: 2750&#8211;61.","DOI":"10.1007\/s10620-015-3677-x"},{"key":"10.3238\/arztebl.m2021.0353_ref50","doi-asserted-by":"crossref","unstructured":"Meyer A, Drouin J, Weill A, Carbonnel F, Dray-Spira R: Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010&#8211;2018. Aliment Pharmacol Ther 2020; 52: 1480&#8211;90.","DOI":"10.1111\/apt.16074"},{"key":"10.3238\/arztebl.m2021.0353_ref51","doi-asserted-by":"crossref","unstructured":"Riis L, Vind I, Politi P, et al.: Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101: 1539&#8211;45.","DOI":"10.1111\/j.1572-0241.2006.00602.x"},{"key":"10.3238\/arztebl.m2021.0353_ref52","doi-asserted-by":"crossref","unstructured":"Yu A, Friedman S, Ananthakrishnan AN: Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis 2020; 26: 1926&#8211;32.","DOI":"10.1093\/ibd\/izz313"},{"key":"10.3238\/arztebl.m2021.0353_ref53","doi-asserted-by":"crossref","unstructured":"Tandon P, Leung K, Yusuf A, Huang VW: Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review. J Clin Gastroenterol 2019; 53: 574&#8211;81.","DOI":"10.1097\/MCG.0000000000001244"},{"key":"10.3238\/arztebl.m2021.0353_ref54","doi-asserted-by":"crossref","unstructured":"Flanagan E, Wright EK, Begun J, et al.: Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. J Crohns Colitis 2020; 14: 1405&#8211;12.","DOI":"10.1093\/ecco-jcc\/jjaa082"},{"key":"10.3238\/arztebl.m2021.0353_ref55","doi-asserted-by":"crossref","unstructured":"Cappell MS: Risks versus benefits of gastrointestinal endoscopy during pregnancy. Nat Rev Gastroenterol Hepatol 2011; 8: 610&#8211;34.","DOI":"10.1038\/nrgastro.2011.162"},{"key":"10.3238\/arztebl.m2021.0353_ref56","unstructured":"Santos MPC, Gomes C, Torres J: Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol 2018; 31: 14&#8211;23."},{"key":"10.3238\/arztebl.m2021.0353_ref57","doi-asserted-by":"crossref","unstructured":"Kehl S, D\u00f6tsch J, Hecher K, et al.: Intrauterine growth restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015\/080, October 2016). Geburtshilfe Frauenheilkd 2017; 77: 1157&#8211;73.","DOI":"10.1055\/s-0043-118908"},{"key":"10.3238\/arztebl.m2021.0353_ref58","doi-asserted-by":"crossref","unstructured":"Lees CC, Stampalija T, Baschat A, et al.: ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56: 298&#8211;312.","DOI":"10.1002\/uog.22134"},{"key":"10.3238\/arztebl.m2021.0353_ref59","doi-asserted-by":"crossref","unstructured":"O&#8217;Gorman N, Wright D, Poon LC, et al.: Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11&#8211;13 weeks&#8217; gestation. Ultrasound Obstet Gynecol 2017; 49: 751&#8211;5.","DOI":"10.1002\/uog.17399"},{"key":"10.3238\/arztebl.m2021.0353_ref60","doi-asserted-by":"crossref","unstructured":"Rolnik DL, Wright D, Poon LC, et al.: Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613&#8211;22.","DOI":"10.1056\/NEJMoa1704559"},{"key":"10.3238\/arztebl.m2021.0353_ref61","doi-asserted-by":"crossref","unstructured":"Seo MR, Chae J, Kim YM, et al.: Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019; 28: 722&#8211;30.","DOI":"10.1177\/0961203319843343"},{"key":"10.3238\/arztebl.m2021.0353_ref62","unstructured":"Canti V, Scarrone M, Lorenzo R de, et al.: Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine. Immunol Med 2021: 1&#8211;7."},{"key":"10.3238\/arztebl.m2021.0353_ref63","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhang Y, Wei Y, Yang H: Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. Arch Gynecol Obstet 2021; 303: 435&#8211;41.","DOI":"10.1007\/s00404-020-05762-5"},{"key":"10.3238\/arztebl.m2021.0353_ref64","doi-asserted-by":"crossref","unstructured":"Guillotin V, Bouhet A, Barnetche T, et al.: Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: a systematic review and meta-analysis. Joint Bone Spine 2018; 85: 663&#8211;8.","DOI":"10.1016\/j.jbspin.2018.03.006"},{"key":"10.3238\/arztebl.m2021.0353_ref65","doi-asserted-by":"crossref","unstructured":"Duley L, Meher S, Hunter KE, Seidler AL, Askie LM: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019.","DOI":"10.1002\/14651858.CD004659.pub3"},{"key":"10.3238\/arztebl.m2021.0353_ref66","doi-asserted-by":"crossref","unstructured":"Hastie R, Tong S, Wikstr\u00f6m A-K, Sandstr\u00f6m A, Hesselman S, Bergman L: Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol 2021; 224: 95.e1&#8211;95.e12.","DOI":"10.1016\/j.ajog.2020.07.023"},{"key":"10.3238\/arztebl.m2021.0353_ref67","doi-asserted-by":"crossref","unstructured":"Ciobanu AM, Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM: Benefits and risks of IgG transplacental transfer. Diagnostics (Basel) 2020; 10: 583","DOI":"10.3390\/diagnostics10080583"},{"key":"10.3238\/arztebl.m2021.0353_ref68","doi-asserted-by":"crossref","unstructured":"Mofors J, Eliasson H, Ambrosi A, et al.: Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro\/SSA autoantibodies in utero. Ann Rheum Dis 2019; 78: 696&#8211;703.","DOI":"10.1136\/annrheumdis-2018-214406"},{"key":"10.3238\/arztebl.m2021.0353_ref69","doi-asserted-by":"crossref","unstructured":"Limaye MA, Buyon JP, Cuneo BF, Mehta-Lee SS: A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. Prenat Diagn 2020; 40: 1066&#8211;76.","DOI":"10.1002\/pd.5709"},{"key":"10.3238\/arztebl.m2021.0353_ref70","doi-asserted-by":"crossref","unstructured":"Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK: Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110: 1542&#8211;8.","DOI":"10.1161\/01.CIR.0000142046.58632.3A"},{"key":"10.3238\/arztebl.m2021.0353_ref71","doi-asserted-by":"crossref","unstructured":"Hutter D, Silverman ED, Jaeggi ET: The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro\/SSA antibodies: a review. Scand J Immunol 2010; 72: 235&#8211;41.","DOI":"10.1111\/j.1365-3083.2010.02440.x"},{"key":"10.3238\/arztebl.m2021.0353_ref72","doi-asserted-by":"crossref","unstructured":"Izmirly PM, Saxena A, Sahl SK, et al.: Assessment of fluorinated steroids to avert progression and mortality in anti-SSA\/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016; 75: 1161&#8211;5.","DOI":"10.1136\/annrheumdis-2015-208311"},{"key":"10.3238\/arztebl.m2021.0353_ref73","doi-asserted-by":"crossref","unstructured":"Jobe AH, Goldenberg RL: Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Am J Obstet Gynecol 2018; 219: 62&#8211;74.","DOI":"10.1016\/j.ajog.2018.04.007"},{"key":"10.3238\/arztebl.m2021.0353_ref74","doi-asserted-by":"crossref","unstructured":"Saxena A, Stevens J, Cetin H, et al.: Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. Sci Rep 2017; 7: 14426.","DOI":"10.1038\/s41598-017-14350-8"},{"key":"10.3238\/arztebl.m2021.0353_ref75","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Hong Y: Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 2018; 25: 1402&#8211;9.","DOI":"10.1111\/ene.13788"},{"key":"10.3238\/arztebl.m2021.0353_ref76","doi-asserted-by":"crossref","unstructured":"Hacohen Y, Jacobson LW, Byrne S, et al.: Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm 2015; 2: e57.","DOI":"10.1212\/NXI.0000000000000057"},{"key":"10.3238\/arztebl.m2021.0353_ref77","doi-asserted-by":"crossref","unstructured":"Tjon JK, Tan-Sindhunata GM, Bugiani M, et al.: Fetal akinesia deformation sequence, arthrogryposis multiplex congenita, and bilateral clubfeet: is motor assessment of additional value for in utero diagnosis? A 10-year cohort study. Prenat Diagn 2019; 39: 219&#8211;31.","DOI":"10.1002\/pd.5411"},{"key":"10.3238\/arztebl.m2021.0353_ref78","unstructured":"Lamb CA, Kennedy NA, Raine T, et al.: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68: 1&#8211;106."},{"key":"10.3238\/arztebl.m2021.0353_ref79","doi-asserted-by":"crossref","unstructured":"Wagner N, Assmus F, Arendt G, et al.: Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2019; 494&#8211;515.","DOI":"10.1007\/s00103-019-02905-1"},{"key":"10.3238\/arztebl.m2021.0353_ref80","unstructured":"Briggs GG, Towers CV, Freeman RK: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia, PA: Wolters Kluwer 2017."},{"key":"10.3238\/arztebl.m2021.0353_ref81","doi-asserted-by":"crossref","unstructured":"Litwinska M, Litwinska E, Lisnere K, Syngelaki A, Wright A, Nicolaides KH: Stratification of pregnancy care based on risk of pre-eclampsia derived from uterine artery doppler at 19&#8211;24 weeks&#8217; gestation. Ultrasound Obstet Gynecol 2021; 58: 360&#8211;8.","DOI":"10.1002\/uog.23640"},{"key":"10.3238\/arztebl.m2021.0353_ref82","doi-asserted-by":"crossref","unstructured":"Chaoui R, Heling K, Mielke G, Hofbeck M, Ge mbruch U: [Quality standards of the DEGUM for performance of fetal echocardiography]. Ultraschall Med 2008; 29: 197&#8211;200.","DOI":"10.1055\/s-2008-1027302"},{"key":"10.3238\/arztebl.m2021.0353_ref83","unstructured":"Merz E, Eichhorn KH, Kaisenberg C, Schramm T: [Updated quality requirements regarding secondary differentiated ultrasound examination in prenatal diagnostics (= DEGUM level II) in the period from 18 + 0 to 21 + 6 weeks of gestation]. Ultraschall Med 2012: 33:&nbsp;593&#8211;6."},{"key":"10.3238\/arztebl.m2021.0353_ref84","doi-asserted-by":"crossref","unstructured":"Kozlowski P, Burkhardt T, Gembruch U, et al.: [DEGUM, \u00d6GUM, SGUM and FMF Germany recommendations for the implementation of first-trimester screening, detailed ultrasound, cell-free DNA screening and diagnostic procedures]. Ultraschall Med 2019: 40: 176&#8211;93.","DOI":"10.1055\/a-0631-8898"},{"key":"10.3238\/arztebl.m2021.0353_ref85","doi-asserted-by":"crossref","unstructured":"Phoon CKL, Kim MY, Buyon JP, Friedman DM: Finding the &#8220;PR-fect&#8221; solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis 2012: 7: 349&#8211;60.","DOI":"10.1111\/j.1747-0803.2012.00652.x"},{"key":"10.3238\/arztebl.m2021.0353_ref86","doi-asserted-by":"crossref","unstructured":"Sonesson SE, Ambrosi A, Wahren-Herlenius M: Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single-center study of 212 anti-Ro52-positive pregnancies. Ultrasound Obstet Gynecol 2019: 54: 87&#8211;95.","DOI":"10.1002\/uog.20214"},{"key":"10.3238\/arztebl.m2021.0353_ref87","doi-asserted-by":"crossref","unstructured":"Bergman G, Wahren-Herlenius M, Sonesson SE: Diagnostic precision of doppler flow echocardiography in fetuses at risk for atrioventricular block. Ultrasound Obstet Gynecol 2010: 36: 561&#8211;6.","DOI":"10.1002\/uog.7532"},{"key":"10.3238\/arztebl.m2021.0353_ref88","doi-asserted-by":"crossref","unstructured":"Kan N, Silverman ED, Kingdom J, Dutil N, Laskin C, Jaeggi E: Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy. Prenat Diagn 2017: 37: 375&#8211;82.","DOI":"10.1002\/pd.5021"},{"key":"10.3238\/arztebl.m2021.0353_ref89","doi-asserted-by":"crossref","unstructured":"Saito M, Silverman E, Golding F, et al.: Effects of transplacental dexamethasone therapy on fetal immune-mediated complete heart block. Fetal Diagn Ther 2021: 48: 183&#8211;8.","DOI":"10.1159\/000513202"},{"key":"10.3238\/arztebl.m2021.0353_ref90","doi-asserted-by":"crossref","unstructured":"Cuneo BF, Sonesson S-E, Levasseur S, et al.: Home monitoring for fetal heart rhythm during anti-Ro pregnancies. J Am Coll Cardiol 2018: 72: 1940&#8211;51.","DOI":"10.1016\/j.jacc.2018.07.076"},{"key":"10.3238\/arztebl.m2021.0353_ref91","unstructured":"Cuneo BF: Fetal bradycardia. In: Yagel S, Silverman NH, Gembruch U (eds): Fetal cardiology: embryology, genetics, physiology, echocardiographic evaluation, diagnosis, and perinatal management of cardiac diseases. Boca Raton: CRC Press, Taylor &amp; Francis Group 2019; 515&#8211;29."},{"key":"10.3238\/arztebl.m2021.0353_ref92","doi-asserted-by":"crossref","unstructured":"Strasburger JF, Wacker-Gussmann A: Congenital heart block in subsequent pregnancies of SSA\/Ro-positive mothers: cutting recurrence in half. J Am Coll Cardiol 2020; 76: 303&#8211;5.","DOI":"10.1016\/j.jacc.2020.05.052"},{"key":"10.3238\/arztebl.m2021.0353_ref93","doi-asserted-by":"crossref","unstructured":"Friedman DM, Kim M, Costedoat-Chalumeau N, et al.: Electrocardiographic QT intervals in infants exposed to hydroxychloroquine throughout gestation. Circ Arrhythm Electrophysiol 2020; 13: e008686.","DOI":"10.1161\/CIRCEP.120.008686"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:05:33Z","timestamp":1700240733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":93,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0353","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}